Neurocrine Biosciences (NBIX) EBITDA (2010 - 2026)

Neurocrine Biosciences' EBITDA history runs 17 years deep, the most recent figure standing at $193.4 million for Q1 2026.

• Quarterly EBITDA rose 719.49% year-over-year to $193.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $788.9 million (up 59.44% YoY) and the FY2025 annual result came in at $619.1 million, up 8.52% from the prior year.
• EBITDA was $193.4 million for Q1 2026 at Neurocrine Biosciences, down from $210.9 million in the prior quarter.
• Across five years, EBITDA topped out at $239.0 million in Q3 2025 and bottomed at -$114.2 million in Q1 2023.
• A 5-year average of $110.8 million and a median of $141.2 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA slumped 3783.87% — and 2026, when it jumped 719.49%.
• Neurocrine Biosciences' EBITDA stood at $103.4 million in 2022, then surged by 45.36% to $150.3 million in 2023, then decreased by 5.52% to $142.0 million in 2024, then surged by 48.52% to $210.9 million in 2025, then dropped by 8.3% to $193.4 million in 2026.
• Business Quant data shows NBIX's EBITDA at $193.4 million in Q1 2026, $210.9 million in Q4 2025, and $239.0 million in Q3 2025.